Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Track APUS with free AI briefings, catalyst countdowns, and dilution alerts.

APUS · Apimeds Pharmaceuticals US, Inc.

Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.

$278,371 Cash on Hand
0.2mo Cash Runway
Follow APUS by email Get an email when APUS reports key news in an SEC filing, pushes back a promised milestone, files for a stock offering, lands on the Downside Radar or has an FDA decision. Free, no account needed.

We send one confirmation email first. Only emails about APUS, unsubscribe in one click. Privacy

📄 Latest SEC Filings in Plain English

Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.

🧪 Trial & FDA Catalysts

📊 Drug Pipeline

DrugIndicationMost advanced trialStatus
Apitox - pure honeybee toxin Multiple Sclerosis Phase 3 · NCT03710655 Unknown
Histamine Osteoarthritis of the Knee Phase 3 · NCT01112722 Completed
honeybee venom (Apitoxin (Korea) Apitox (USA)) Osteoarthritis of the Knee Phase 2 · NCT00949754 Completed

Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it

💰 Cash Runway & Dilution Risk

APUS holds $278,371 in cash and short-term investments (as of Jun 30, 2026) and burns about $3.9M/quarter from operations, an estimated runway of 0.2 months at that rate (BioRadar estimate, not company guidance).

Dilution pressure: 55 · Elevated

Recent financing filings on SEC EDGAR:

Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when APUS files for a raise →

👥 Who Owns APUS

Insiders 100% Institutions 0% Public and other holders 0%
HolderTypeShares% of sharesAs of
Apimeds Inc. 5%+ holder (13D) 4,316,618 233.63% 2026-05-07
Inscobee Inc.
10% owner
Insider 2,099,747 113.65% 2025-05-12
Ayrton Capital LLC Institution (13G, 5%+) 1,397,021 75.61% 2025-12-31
Erik C. Emerson
Chief Executive Officer, Director · +562,279 options
Insider 750,000 40.59% 2025-05-16
Jakap Koo
Director · +18,780 options
Insider 643,885 34.85% 2025-05-12
Christopher Kim
Chairman and CMO, Director · +3,000 options
Insider 277,500 15.02% 2025-05-16

Share count 1,847,626 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the largest 13F holders. Sources have different dates, so the split is approximate. Source: SEC EDGAR.

Get the full APUS picture

The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for APUS and every other ticker you follow. Card required, cancel anytime.

Start 7-day free trial →

Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.